Furthermore, increased AREG secretion has been observed in RAS/BRAF WT CRC cells in response to cetuximab treatment, and treatment with recombinant AREG conferred cetuximab resistance in a cell line-dependent manner, though to a lesser extent compared to TGFα [82]. Here, BRAF is linked to colorectal carcinoma.